Skip to main navigation menu Skip to main content Skip to site footer

Vol. 13 No. 01 (2026)
International Multidisciplinary Journal for Research & Development

Articles

EVALUATION OF THE EFFICACY OF THE ANGIOTENSIN RECEPTOR–NEPRILYSIN INHIBITOR (SACUBITRIL/VALSARTAN) IN PATIENTS WITH CHRONIC HEART FAILURE AND RENAL DYSFUNCTION.

Published 2026-01-30

  • Iqboljon Mullaboyev Tolibov, Durdona Shuhratovna Adilova

Iqboljon Mullaboyev Tolibov, Durdona Shuhratovna Adilova
Tashkent State Medical University

Abstract

Chronic heart failure (CHF) is frequently accompanied by renal dysfunction, forming cardiorenal syndrome and significantly worsening prognosis. Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has demonstrated superior outcomes compared with conventional renin–angiotensin system blockade; however, data in patients with impaired renal function remain limited. To evaluate the clinical efficacy, cardiac remodeling effects, and renal safety of sacubitril/valsartan in patients with chronic heart failure and renal dysfunction.

Keywords

Chronic heart failure, renal dysfunction, cardiorenal syndrome, sacubitril/valsartan, ARNI

PDF

References

  1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7–11.
  2. Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–1434.
  3. Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure. Eur Heart J. 2014;35(7):455–469.
  4. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure. J Am Coll Cardiol. 2006;47(10):1987–1996.
  5. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–1539.
  6. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577–585.
  7. Zannad F, Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018;138(9):929–944.
  8. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327(10):669–677.
  9. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor–associated elevations in serum creatinine. Arch Intern Med. 2000;160(5):685–693.
  10. Jhund PS, McMurray JJV. Neprilysin inhibition in heart failure: a clinical perspective. Heart. 2016;102(17):1342–1352.
  11. Volpe M, Rubattu S, Burnett J. Natriuretic peptides in cardiovascular diseases. Eur Heart J. 2018;39(5):386–395.
  12. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
  13. Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in heart failure patients. Eur J Heart Fail. 2019;21(8):998–1007.
  14. Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin–neprilysin inhibition in heart failure. Circulation. 2018;138(6):542–548.
  15. Silverman DN, Plante TB, Infeld M, et al. Barriers to sacubitril/valsartan use in clinical practice. J Am Heart Assoc. 2020;9(11):e015420.
  16. Solomon SD, Rizkala AR, Gong J, et al. Angiotensin receptor–neprilysin inhibition and ventricular remodeling. JAMA. 2019;322(11):1085–1095.
  17. Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril/valsartan on renal function. Lancet. 2016;388(10043):475–485.
  18. Voors AA, Gori M, Senni M, et al. Renal effects of neprilysin inhibition in heart failure. Eur J Heart Fail. 2015;17(5):510–517.
  19. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction in real-world practice. JACC Heart Fail. 2020;8(3):191–201.
  20. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin–angiotensin system inhibition for heart failure. Am Heart J. 2017;174:55–63.
  21. McDonagh TA, Metra M, Adamo M, et al. 2023 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(4):359–372

Downloads

Download data is not yet available.